Last reviewed · How we verify

smoked plum

Guangxi Medical University · Phase 3 active Small molecule Under review

smoked plum is a Small molecule drug developed by Guangxi Medical University. It is currently in Phase 3 development for Investigational treatment for various conditions.

Smoked plum's mechanism of action is not well-documented.

Smoked plum is a traditional East Asian ingredient used in cuisine and medicine, and it has been studied in clinical trials for various conditions, including liver cancer, plaque type psoriasis, and allergies to fish, shrimp, and crab. Smoked plum has been identified as a cannabinoid CB1 receptor antagonist, a type of small molecule that acts as an antagonist to the cannabinoid receptor 1.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namesmoked plum
SponsorGuangxi Medical University
ModalitySmall molecule
PhasePhase 3

Mechanism of action

There is limited information available on the exact mechanism of action of smoked plum, making it difficult to provide a detailed explanation.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about smoked plum

What is smoked plum?

smoked plum is a Small molecule drug developed by Guangxi Medical University, indicated for Investigational treatment for various conditions.

How does smoked plum work?

Smoked plum's mechanism of action is not well-documented.

What is smoked plum used for?

smoked plum is indicated for Investigational treatment for various conditions.

Who makes smoked plum?

smoked plum is developed by Guangxi Medical University (see full Guangxi Medical University pipeline at /company/guangxi-medical-university).

What development phase is smoked plum in?

smoked plum is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing